Serum magnesium levels may influence development and progression of CKD metabolic disorders: Study

A new study published in the journal of Risk Management and Healthcare Policy showed that the frequency of magnesium metabolic abnormalities rises steadily with the severity of chronic kidney disease (CKD), peaking in stage G5.

Chronic kidney disease patients have been shown to have a magnesium metabolic imbalance. However, little is known about the blood magnesium levels of patients with non-dialysis-dependent CKD (NDD-CKD) and how they relate to mineral-skeletal metabolic disorder (CKD-MBD). Thus, this research examined how blood magnesium levels vary over time in patients with non-dialysis-dependent chronic kidney disease and assess how these variations relate to indicators of mineral metabolism (calcium, phosphorus, iPTH, and alkaline phosphatase).

Data from 156 patients with stage 3–5 CKD (G3–G5) who were hospitalized to Handan First Hospital between March 2017 and December 2019 were retrospectively analyzed. The levels of alkaline phosphatase (AKP), intact parathyroid hormone (iPTH), calcium, phosphorus, and magnesium in the serum were measured. Based on their serum magnesium levels, the patients were divided into groups with hypomagnesemia, normal magnesium, and hypermagnesemia. Analysis was done on connections between magnesium levels and phosphorus, AKP, and iPTH levels.